NEW ZEALAND DATA SHEET

1. PRODUCT NAME

BOOSTRIX Combined diphtheria-tetanus-acellular pertussis (dTpa) suspension for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

BOOSTRIX dTpa vaccine is a sterile suspension which contains diphtheria toxoid, tetanus toxoid and three purified antigens of Bordetella pertussis [pertussis toxoid (PT), pertussis filamentous haemagglutinin (FHA) and pertussis 69 kilodalton (kDa) outer membrane protein (OMP)] adsorbed onto aluminium salts.

1 dose (0.5 mL) contains:

Diphtheria toxoid¹ not less than 2 International Units (IU) (2.5 Lf)

Tetanus toxoid¹ not less than 20 International Units (IU) (5 Lf)

Bordetella pertussis antigens

- Pertussis toxoid¹ 8 micrograms
- Filamentous Haemagglutinin¹ 8 micrograms
- Pertactin¹ 2.5 micrograms

¹adsorbed on aluminium hydroxide, hydrated (Al(OH)₃) 0.3 milligrams Al³⁺

and aluminium phosphate (AlPO₄) 0.2 milligrams Al³⁺

The diphtheria toxoid, tetanus toxoid and acellular pertussis vaccine (dTpa) components are adsorbed on 0.5 mg aluminium and suspended in isotonic sodium chloride.

For the full list of excipients, see section 6.1 List of excipients.

3. PHARMACEUTICAL FORM

BOOSTRIX is a turbid white suspension for injection.

Upon storage a white deposit and clear supernatant can be observed. This is a normal finding.

4. CLINICAL PARTICULARS

indications

BOOSTRIX is indicated for booster vaccination against diphtheria, tetanus and pertussis of individuals aged four years and older.

4.2 Dose and method of administration

Dose

Each dose consists of a 0.5 mL ready to use sterile suspension.

Method of administration
BOOSTRIX is administered by deep intramuscular injection, preferably in the deltoid region. THE VACCINE SHOULD NEVER BE ADMINISTERED INTRAVENOUSLY.

**Immunisation Schedule**

BOOSTRIX can be given in accordance with the current local medical practices for booster vaccination with adult-type combined diphtheria-tetanus vaccine, when a booster against pertussis is desired.

Repeat vaccination against diphtheria, tetanus and pertussis should be performed at intervals as per official recommendations (generally 10 years).

BOOSTRIX can be used in the management of tetanus prone injuries in persons who have previously received a primary vaccination series of tetanus toxoid vaccine. Tetanus immunoglobulin should be administered concomitantly in accordance with official recommendations.

**4.3 Contraindications**

BOOSTRIX should not be administered to subjects with known hypersensitivity to any component of the vaccine, or to subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus or pertussis vaccines.

As with other vaccines, the administration of BOOSTRIX should be postponed in subjects suffering from acute severe febrile illness. The presence of a minor infection, however, is not a contraindication.

BOOSTRIX is contraindicated if the subject has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis-containing vaccine. In these circumstances, pertussis vaccination should be discontinued and the vaccination course should be continued with diphtheria and tetanus vaccines.

BOOSTRIX should not be administered to subjects who have experienced transient thrombocytopenia or neurological complications following an earlier immunisation against diphtheria and/or tetanus (for convulsions or hypotonic-hyporesponsive episodes see section 4.4 Special warnings and precautions for use).

**4.4 Special warnings and precautions for use**

**BOOSTRIX should under no circumstances be administered intravenously.**

It is good clinical practice that immunisation should be preceded by a review of the medical history (especially with regard to previous immunisation and possible occurrence of undesirable events) and a clinical examination.

If any of the following events have occurred in temporal relation to receipt of pertussis containing vaccines, the decision to give doses of pertussis containing vaccines, should be carefully considered. There may be circumstances, such as a high incidence of pertussis, when the potential benefits outweigh possible risks, particularly since these events are not associated with permanent sequelae.

- Temperature of $\geq 40.0^\circ C$ within 48 hours of vaccination, not due to another identifiable cause.
- Collapse or shock-like state (hypotonic-hyporesponsive episode) within 48 hours of vaccination.
- Persistent, inconsolable crying lasting $\geq 3$ hours, occurring within 48 hours of vaccination.
- Convulsions with or without fever, occurring within 3 days of vaccination.
In children with progressive neurological disorders, including infantile spasms, uncontrolled epilepsy or progressive encephalopathy, it is better to defer pertussis (Pa or Pw) immunisation until the condition is corrected or stable. However, the decision to give pertussis vaccine must be made on an individual basis after careful consideration of the risks and benefits.

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine.

BOOSTRIX should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects. Firm pressure should be applied to the injection site (without rubbing) for at least two minutes.

A history or a family history of convulsions and a family history of an adverse event following DTP vaccination do not constitute contraindications.

Human Immunodeficiency Virus (HIV) infection is not considered a contraindication for diphtheria, tetanus and pertussis (whole-cell or acellular) immunisation. However in patients with immunodeficiency or in patients receiving immunosuppressive therapy, an adequate immunologic response may not be achieved. In these patients, when tetanus vaccine is needed for tetanus prone wound, plain tetanus vaccine should be used.

Extremely rare cases of collapse or shock-like state (hypotonic-hyporesponsiveness episode) and convulsions within 2 to 3 days of vaccination have been reported in DTPa and DTPa combination vaccines.

Syncope (fainting) can occur following, or even before, any vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from faints.

As with any vaccine, a protective immune response may not be elicited in all vaccinees.

4.5 Interaction with other medicines and other forms of interaction

Concomitant use with other inactivated vaccines and with immunoglobulin is unlikely to result in interference with the immune responses.

When considered necessary, BOOSTRIX can be administered simultaneously with other vaccines or immunoglobulins.

If BOOSTRIX is to be given at the same time as another injectable vaccine or immunoglobulin, the products should always be administered at different sites.

BOOSTRIX must not be mixed with other vaccines.

4.6 Fertility, pregnancy and lactation

Pregnancy

(Category B1)

Safety data from a prospective observational study where BOOSTRIX was administered to pregnant women during the third trimester (793 pregnancy outcomes) as well as data from post-marketing surveillance where pregnant women were exposed to BOOSTRIX or to BOOSTRIX-IPV (dTpa-inactivated poliovirus vaccine) indicate no vaccine related adverse effect on pregnancy or on the health of the foetus/newborn child.

The use of BOOSTRIX may be considered during the third trimester of pregnancy.
Human data from prospective clinical studies on the use of BOOSTRIX during the first and second trimester of pregnancy are not available.

Limited data indicate that maternal antibodies may reduce the magnitude of the immune response to some vaccines in infants born from mothers vaccinated with BOOSTRIX during pregnancy. The clinical relevance of this observation is unknown.

Non-clinical data obtained with BOOSTRIX reveal no specific hazard for humans based on conventional studies of embryo-foetal development in rats and rabbits, and also of parturition and postnatal toxicity in rats (up to the end of the lactation period).

BOOSTRIX may be used during pregnancy when the possible advantages outweigh the possible risks for the foetus. When protection against tetanus is sought, consideration should be given to tetanus or combined diphtheria-tetanus vaccines.

**Breast-feeding**

The safety of BOOSTRIX when administered to breast-feeding women has not been evaluated.

It is unknown whether BOOSTRIX is excreted in human breast milk.

BOOSTRIX should only be used during breast-feeding when the possible advantages outweigh the potential risks.

**Fertility**

No human data available. Non-clinical data obtained with BOOSTRIX reveal no specific hazard for humans based on conventional studies of female fertility in rats and rabbits.

**4.7 Effects on ability to drive and use machines**

The vaccine is unlikely to produce an effect on the ability to drive and use machines.

**4.8 Undesirable effects**

**Tabulated list of adverse reactions**

**Clinical trial data**

The safety profile below is based on data from clinical trials where BOOSTRIX was administered to 839 children (from 4 to 9 years of age) and 1931 adults, adolescents and children (above 10 years of age).

Adverse reactions reported are listed according to the following frequency:

- **Very common:** \( \geq 1/10 \)
- **Common:** \( \geq 1/100 \) and \( <1/10 \)
- **Uncommon:** \( \geq 1/1000 \) and \( <1/100 \)
- **Rare:** \( \geq 1/10,000 \) and \( <1/1000 \)
- **Very rare:** \( <1/10,000 \)

**Children from 4 to 9 years of age**

**Infections and infestations**
Uncommon: upper respiratory tract infection

**Metabolism and nutrition disorders**
Common: anorexia

**Psychiatric disorders**
Very common: irritability

**Nervous system disorders**
Very common: somnolence
Common: headache
Uncommon: disturbances in attention

**Eye disorders**
Uncommon: conjunctivitis

**Gastrointestinal disorders**
Common: diarrhoea, vomiting, gastrointestinal disorders

**Skin and subcutaneous tissue disorders**
Uncommon: rash

**General disorders and administration site conditions**
Very common: injection site reactions (including pain, redness and swelling), fatigue
Common: fever ≥ 37.5 °C (including fever > 39 °C),
Uncommon: other injection site reactions (such as induration), pain

*Adults, adolescents and children from the age of 10 years onwards*

**Infections and infestations**
Uncommon: upper respiratory tract infection, pharyngitis

**Blood and lymphatic system disorders**
Uncommon: lymphadenopathy

**Nervous system disorders**
Very common: headache
Common: dizziness
Uncommon: syncope

**Respiratory, thoracic and mediastinal disorders**
Uncommon: cough
**Gastrointestinal disorders**
Common: nausea, gastrointestinal disorders
Uncommon: diarrhoea, vomiting

**Skin and subcutaneous tissue disorders**
Uncommon: hyperhidrosis, pruritus, rash

**Musculoskeletal and connective tissue disorders**
Uncommon: arthralgia, myalgia, joint stiffness, musculoskeletal stiffness

**General disorders and administration site conditions**
Very common: injection site reactions (including pain, redness and swelling), fatigue, malaise
Common: fever \(\geq 37.5 \, ^\circ C\), injection site reactions (such as injection site mass and injection site abscess sterile)
Uncommon: fever \(> 39 \, ^\circ C\), influenza like illness, pain

**Post-marketing experience**

**Blood and lymphatic system disorders**
Rare: angioedema

**Immune system disorders**
Very rare: allergic reactions, including anaphylactic and anaphylactoid reactions

**Nervous system disorders**
Rare: convulsions (with or without fever)

**Skin and subcutaneous tissue disorders**
Rare: urticaria

**General disorders and administration site conditions**
Rare: extensive swelling of the vaccinated limb, asthenia

Data on 146 subjects suggest a small increase in local reactogenicity (pain, redness, swelling) with repeated vaccination according to a 0, 1, 6 months schedule in adults (> 40 years of age).

Subjects fully primed with 4 doses of DTPw followed by a BOOSTRIX dose around 10 years of age show an increase of local reactogenicity after an additional BOOSTRIX dose administered 10 years later.

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions via: [https://nzphvc.otago.ac.nz/reporting](https://nzphvc.otago.ac.nz/reporting).
4.9 Overdose

Cases of overdose have been reported during post-marketing surveillance. Adverse events following overdosage, when reported, were similar to those reported with normal vaccine administration.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Bacterial vaccines combined, ATC code: J07AJ52.

Mechanism of action

BOOSTRIX (dTpa vaccine), induces antibodies against all vaccine components.

Clinical efficacy and safety

Immune response results to the diphtheria, tetanus and acellular pertussis components in clinical studies are presented in the table below. Approximately one month following booster vaccination with BOOSTRIX, the following seroprotection / seropositivity rates were observed:

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Seroprotection / Seropositivity</th>
<th>Adults and adolescents from the age of 10 years onwards, at least 1690 subjects (% vaccinees)</th>
<th>Children from 4 to 9 years of age, at least 415 subjects (% vaccinees)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphtheria</td>
<td>≥ 0.1 IU/ml*</td>
<td>97.2%</td>
<td>99.8%</td>
</tr>
<tr>
<td>Tetanus</td>
<td>≥ 0.1 IU/ml*</td>
<td>99.0%</td>
<td>100.0%</td>
</tr>
<tr>
<td>Pertussis:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Pertussis toxoid</td>
<td>≥ 5 EL.U/ml</td>
<td>97.8%</td>
<td>99.0%</td>
</tr>
<tr>
<td>- Filamentous haemagglutinin</td>
<td>≥ 5 EL.U/ml</td>
<td>99.9%</td>
<td>100.0%</td>
</tr>
<tr>
<td>- Pertactin</td>
<td>≥ 5 EL.U/ml</td>
<td>99.4%</td>
<td>99.8%</td>
</tr>
</tbody>
</table>

*cut-off accepted as indicative of protection

Results of the comparative studies with commercial dT vaccines indicates that the degree and duration of protection would not be different from those obtained with these vaccines.

Protective efficacy of pertussis

There is currently no correlate of protection defined for pertussis; however, the protective efficacy of GlaxoSmithKline Biologicals’ DTPa (INFANRIX) vaccine against WHO-defined typical pertussis (≥ 21 days of paroxysmal cough with laboratory confirmation) was demonstrated in the following 3-dose primary studies:

- a prospective blinded household contact study performed in Germany (3, 4, 5 months schedule) based on data collected from secondary contacts in households where there was an index case with typical pertussis, the protective efficacy of the vaccine was 88.7%.
Protection against laboratory confirmed mild disease, defined as 14 days or more of cough of any type was 73% and 67% when defined as 7 days or more of cough of any type; and

- an NIH sponsored efficacy study performed in Italy (2, 4, 6 months schedule). The vaccine efficacy was found to be 84%. When the definition of pertussis was expanded to include clinically milder cases with respect to type and duration of cough, the efficacy of INFANRIX was calculated to be 71% against >7 days of any cough and 73% against >14 days of any cough.

In a follow-up of the same cohort, the efficacy was confirmed up to 5 years after completion of primary vaccination without administration of a booster dose of pertussis. The study assessed duration of protection of INFANRIX given in a 3 dose schedule to infants. A similar duration of protection cannot be assumed to apply to older children or adults given a single dose of BOOSTRIX, regardless of previous vaccination against pertussis.

Although the protective efficacy of BOOSTRIX has not been demonstrated in adolescents and adult age groups, vaccinees in these age groups who received BOOSTRIX achieved anti-pertussis antibody titres greater than those in the German household contact study where the protective efficacy of INFANRIX was 88.7%.

There are currently no data which demonstrate a reduction of transmission of pertussis after immunisation with BOOSTRIX. However, it could be expected that immunisation of immediate close contacts of newborn infants, such as parents, grandparents healthcare workers and childcare workers would reduce exposure of pertussis to infants not yet adequately protected through immunisation.

**Persistence of immunity to diphtheria, tetanus and pertussis after vaccination with BOOSTRIX in children, adolescents and adults**

The following seroprotection / seropositivity rates were observed 3 to 3.5 years, 5 to 6 years and 10 years following vaccination with BOOSTRIX:

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Seroprotection/seropositivity</th>
<th>Adults and adolescents from the age of 10 years onwards (% vaccinees)</th>
<th>Children from the age of 4 years onwards (% vaccinees)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>3-3.5 years persistence</td>
<td>5 years persistence</td>
</tr>
<tr>
<td></td>
<td>Adult</td>
<td>Adolescent</td>
<td>Adult</td>
</tr>
<tr>
<td>Diphtheria</td>
<td>≥ 0.1 IU/ml*</td>
<td>71.2%</td>
<td>91.6%</td>
</tr>
<tr>
<td></td>
<td>≥ 0.016 IU/ml*</td>
<td>97.4%</td>
<td>100%</td>
</tr>
<tr>
<td>Tetanus</td>
<td>≥ 0.1 IU/ml</td>
<td>94.8%</td>
<td>100%</td>
</tr>
<tr>
<td>Pertussis</td>
<td>Pertussis toxoid</td>
<td>90.6%</td>
<td>81.6%</td>
</tr>
<tr>
<td></td>
<td>Filamentous haemagglutinin</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td>Pertactin</td>
<td>94.8%</td>
<td>99.2%</td>
</tr>
</tbody>
</table>

* Percentage of subjects with antibody concentrations associated with protection against disease (≥ 0.1 IU/ml by ELISA assay or ≥ 0.016 IU/ml by an in-vitro Vero-cell neutralisation assay).

BOOSTRIX administered in subjects ≥40 years of age with an incomplete, unknown or no history of a primary series of diphtheria and tetanus toxoid vaccination history induced an antibody
response against pertussis in more than 98.5% of adults and provided seroprotection against diphtheria and tetanus in 81.5% and 93.4% of adults respectively.

Two subsequent doses maximised the vaccine response against diphtheria and tetanus when administered at one and six months (99.3% and 100% respectively).

**Vaccination with second dose of BOOSTRIX**

The immunogenicity of BOOSTRIX, administered 10 years after a previous booster dose with BOOSTRIX or reduced-antigen content diphtheria, tetanus and acellular pertussis vaccines has been evaluated in adults. One month after the decennial BOOSTRIX dose, >99 % of subjects were seroprotected against diphtheria and tetanus and all were seropositive for antibodies against pertussis antigens PT, FHA and PRN.

5.2 **Pharmacokinetic properties**

Evaluation of pharmacokinetic properties is not required for vaccines.

5.3 **Preclinical safety data**

Preclinical data reveal no special hazard for humans based on conventional studies of safety and toxicity.

6. **PHARMACEUTICAL PARTICULARS**

6.1 **List of excipients**
Aluminium hydroxide, aluminium phosphate, sodium chloride and water for injections.

*Residues:*
Formaldehyde, polysorbate 80 and glycine.

6.2 **Incompatibilities**

BOOSTRIX must not be mixed with other vaccines.

6.3 **Shelf life**

3 years.

6.4 **Special precautions for storage**

Store in a refrigerator (+2°C – +8°C).

DO NOT FREEZE. Discard if vaccine has been frozen.

6.5 **Nature and contents of container**

BOOSTRIX is presented in a prefilled syringe in single dose pack sizes of 1 or 10.

The prefilled syringes are made of neutral glass type I, which conforms to European Pharmacopoeia requirements.

Not all pack sizes may be distributed in New Zealand.

6.6 **Special precautions for disposal and other handling**
All parenteral drug and vaccine products should be inspected visually for any particulate matter or discolouration prior to administration. Before use of BOOSTRIX, the vaccine should be well shaken to obtain a homogenous turbid suspension. Discard the vaccine if it appears otherwise.

This product is for use by one patient on a single occasion.

Any unused product or waste material should be disposed of in accordance with local requirements.

7. MEDICINE SCHEDULE

Prescription Medicine

8. SPONSOR

GlaxoSmithKline NZ Limited
Private Bag 106600
Downtown
Auckland
NEW ZEALAND

Phone: (09) 367 2900
Facsimile: (09) 367 2910

9. DATE OF FIRST APPROVAL

Date of publication in the New Zealand Gazette of consent to distribute the medicine: 9 November 2000

10. DATE OF REVISION OF THE TEXT

14 November 2018

Summary table of changes:

<table>
<thead>
<tr>
<th>Section changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>Data Sheet re-format</td>
</tr>
<tr>
<td>2</td>
<td>Added cross reference to section 6.1</td>
</tr>
<tr>
<td>4.8</td>
<td>Added information on reporting of suspected adverse reactions</td>
</tr>
<tr>
<td>4.9</td>
<td>Added mandatory statement regarding overdose management</td>
</tr>
<tr>
<td>5.1</td>
<td>Added pharmacotherapeutic group and ATC code</td>
</tr>
<tr>
<td>5.2</td>
<td>Added Pharmacokinetic properties section</td>
</tr>
<tr>
<td>5.3</td>
<td>Added Preclinical safety data section</td>
</tr>
<tr>
<td>6.2</td>
<td>Added Incompatibilities section</td>
</tr>
<tr>
<td>6.3</td>
<td>Added shelf life</td>
</tr>
<tr>
<td>6.4</td>
<td>Removed information regarding expiry date on the packaging</td>
</tr>
<tr>
<td></td>
<td>Revised container details and added statement regarding availability in New Zealand</td>
</tr>
<tr>
<td>---</td>
<td>-----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>6.6</td>
<td>Added Special precautions for disposal and other handling section</td>
</tr>
<tr>
<td>9</td>
<td>Added date of first approval</td>
</tr>
<tr>
<td>End of document</td>
<td>Updated trade mark statement and copyright statements</td>
</tr>
<tr>
<td>All</td>
<td>Minor editorial updates throughout the document</td>
</tr>
</tbody>
</table>

Version 8.0

Trade marks are owned by or licensed to the GSK group of companies.

© 2018 GSK group of companies or its licensor.